Over the past six years, Dr. Teresa Lavoie has developed, managed, and overseen the sale of patent portfolios worth more than $33 billion in deal value. Her international practice focuses on strategic patent counseling, prosecution, and portfolio development advice, including patent opinions, due diligence, freedom-to-operate analyses, and life cycle management strategies. Dr. Lavoie’s clients range from start-up and emerging companies developing life-saving therapeutics and diagnostics to academic and research institutions inventing disruptive platform technologies for the biotechnology and biopharma industries. She has extensive experience in the areas of small-molecule and biologic pharmaceuticals (including antibody technologies and immunotherapies, such as CAR-T therapies), drug formulation and drug delivery technologies, diagnostics, clean and alternative (animal- and environmentally-friendly) food technologies, protein biochemistry and engineering, cell systems engineering, nanotechnologies, plant biotechnology and genomics, and green/environmental chemistries. Dr. Lavoie also has significant transactional experience in various aspects of IP licensing, including sponsored research, feasibility, and development and commercialization agreements.
Dr. Lavoie’s clients are located in the major biotechnology, academic/research institution, and start-up clusters around the country and the world, including San Francisco, Cambridge/Boston, and San Diego. Representative clients include: 10x Genomics, First Wave Bio, IFM Due, CytomX Therapeutics, Samumed, Cadent Therapeutics, Kyverna Therapeutics, Coherus BioSciences, Cellphire, Impossible Foods, Albireo Pharmaceuticals, Avanir Pharmaceuticals, Carmot Therapeutics, Concert Pharmaceuticals, Seattle Genetics, HCW Biologics, Pivot Bio, Chinook Therapeutics, Gasherbrum Bio, Annapurna Bio, Seelos Therapeutics, Array BioPharma (prior to its acquisition by Pfizer for $11.4B), IFM Therapeutics (prior to its acquisition by BMS for $2.2B), IFM Tre (prior to its acquisition by Novartis for $1.6B), Loxo Oncology (prior to acquisition by Eli Lilly for $8 billion), and Onyx Pharmaceuticals (prior to acquisition by Amgen for $9.7 billion).
In addition to her work on behalf of clients, Dr. Lavoie runs the firm’s industry-leading Patent Prosecution Boot Camp, an immersive 2.5-day program designed to intensely train junior attorneys and patent agents of the firm and firm clients in the skills of strategic and value-focused patent prosecution.
Dr. Lavoie’s passion for advancing women in the legal industry and her involvement in the recruitment, retention, and advancement of women in both STEM and law has been a hallmark of her legal practice and volunteer commitments throughout her career. For three years, she chaired Fish & Richardson’s EMPOWER (Enrichment, Mentorship, Partnering, Opportunities, Wisdom, Excellence, and Responsibility) Initiative, which seeks to address issues of unique importance to women in the legal profession. She has also been a member of the firm’s compensation committee for four years. In addition, Dr. Lavoie serves as co-chair of the equity committee for Minnesota Women Lawyers, a volunteer organization dedicated to advancing the success of women attorneys and striving for a just society.
Recently, Dr. Lavoie endowed the Anna E. Lavoie Memorial Lectureship at Providence College in tribute to her late mother. Its purpose is to encourage undergraduates to consider a wide array of career paths in the sciences through interaction with distinguished scientists and other professionals. She is also an adjunct professor at the University of Minnesota Law School, teaching biotechnology patent law.
Prior to joining Fish, Dr. Lavoie worked as an intellectual property specialist for Epix Pharmaceuticals Inc. (1996-2000), as a special projects coordinator for Environmental Waste Management Associates Inc. (1995-1996), and as a research assistant at Princeton University (1990-1995).
Selected Presentations and Publications
Dr. Lavoie has numerous scientific publications directed to her doctoral research studying the structure-function implications and energetics of protein folding and protein-DNA interactions.
Dr. Lavoie also routinely presents at various life science patent and industry meetings, including the firm’s Life Science Summits, its Boston Biotech Seminar Series, and its Twin Cities Patents on Tap Series.
“Life Sciences 2020 Year in Review,” presented with Chad Shear, Fish Life Sciences Webinar Series (January 27, 2021).
“Pandemic-related IP: Patents on Vaccines, Treatments, and Diagnostics and the Open COVID Pledge,” speaker, 21st Annual Berkeley-Stanford Advanced Patent Law Institute (APLI) (December 10, 2020).
“Patent Strategies for Biospecific Antibodies,” speaker, Chinese Antibody Society’s “Revisiting the Perspectives of Bispecific Antibodies under the COVID-19 Pandemic” Virtual Conference (December 5, 2020).
“The Promise of Cell and Gene Therapies: Regulatory and Reimbursement Roadblocks,” speaker, Xconomy: Xcelerating Life Sciences – New York & Philadelphia (December 3, 2020).
“How To Prevent a Terrible, Horrible, No Good, Very Bad Day for Your Life Sciences Start-up: Lessons Learned From Company Formation, Drug Development, Partnering, and Due Diligence Nightmares,” speaker, Fish Life Sciences Webinar (December 2, 2020).
“Show Me The Money,” speaker, Bio Integrates 2020 (November 16, 2020).
“Structuring Biotech & Pharma Startup Portfolios for Global Impact, Value, and Partnering,” speaker, NJIPLA’s Pharmaceutical/Chemical Patent Practice Update Webinar Series (October 21, 2020).
“Structuring Biotech & Pharma Startup Portfolios for Global Impact, Value, and Partnering,” presented with Angela Follett, Fish Life Sciences Webinar Series (July 30, 2020).
“Navigating to the Safe Harbor: What to Know in Advance,” presented with Brian Coggio, Fish Life Sciences Webinar Series (July 21, 2020).
“How to Build Your Life Sciences Patent Due Diligence Team,” co-authored with Chad Shear, The Recorder (July 20, 2020).
“Special Topics Related to Obviousness in the Context of Drug Development,” presented with Angela Follett, Fish Life Sciences Webinar Series (June 23, 2020).
“The Data Room in Patent Due Diligence: Perspectives from Two Doors,” co-authored with Chad Shear, The Recorder (May 29, 2020).
Represents Loxo Oncology in all aspects of patent counseling, including the development of life cycle strategies, related to its lead product larotrectinib (LOXO-101) and other oncology products for patients with genetically defined cancers.
Represents Impossible Foods in patent counseling related to development of its plant-based meat products, and Perfect Day Foods in patent counseling related to development of its animal-free dairy products.
Represented Onyx Pharmaceuticals in the development of its patent portfolios and life cycle strategies related to its Kyprolis® (carfilzomib) product and second generation proteasome inhibitor products prior to Onyx’s acquisition by Amgen for $10.4B.
Represented IFM Therapeutics in the development of a patent portfolio directed to its modulators of the innate immune system and handled IP due diligence related to the acquisition of two of its oncology programs by Bristol-Myers Squibb in a deal valued at $2.3 billion.
Represents IFM Due in developing a patent portfolio for its suite of small-molecule antagonists, including handling IP due diligence for an option agreement with Novartis in a deal valued at $840 million.
Represented IFM Tre to develop a patent portfolio around its suite of small-molecule antagonists and handled IP due diligence related to its acquisition by Novartis for $1.575 billion.
Represented Array BioPharma in patent prosecution, counseling, and opinion work, as well as coordinated its patent and regulatory exclusivity strategies, leading to an acquisition by Pfizer for $11.4 billion.
Minnesota Lawyer named Dr. Lavoie “Attorney of the Year” (2019, 2017).
Winner of the “2019 Diversity Leader Award” from Profiles in Diversity.
Dr. Lavoie is recognized as a 2017-2021 WIPR Leader, a 2016-2020 “Top Women in IP” by Managing Intellectual Property, an “IP Star” by Managing Intellectual Property (2013-2020), a “Leading Patent Professional” by IAM Patent 1000, and a 2016-2020 “Life Sciences IP Star” by LMG Life Sciences. In 2015, she received a “Women Worth Watching” Award from Profiles in Diversity Journal. In 2009, she was named a Top 25 “Women to Watch” by The Minneapolis/St. Paul Business Journal and in 2006 she was voted an “Up and Coming Lawyer” by Minnesota Lawyer.
- IP Licensing, Transactions, and Agreements
- Opinions and Strategic Counseling
- Patent Portfolio Management
- Patent Prosecution
- Startup and Early-Stage Companies
J.D. magna cum laude, Order of the Coif, University of Minnesota Law School (2002)
Ph.D., Chemistry, Princeton University (1996)
M.A., Chemistry, Princeton University (1993)
B.S. summa cum laude, Chemistry, Providence College (1989)
- U.S. Patent and Trademark Office 1998
- Minnesota 2003
Member, Fish & Richardson Management Committee
January 27th, 2021 | 1:30 pm EST
Life Sciences Webinar Series | 2020 Year in Review
February 2nd, 2021 | 9:00 am GMT
LSX World Congress 2021
January 6th, 2021 | 4:00 pm GMT
One Nucleus: BioWednesday Webinar - How to Get the Most Out of a Virtual JP Morgan Week
December 10th, 2020 | 11:40 am PST
21st Annual Berkeley-Stanford Advanced Patent Law Institute (APLI)
December 3rd, 2020 | 10:30 am EST
Xconomy: Xcelerating Life Sciences - New York & Philadelphia
December 5th, 2020 | 8:00 am EST
Chinese Antibody Society (CAS): Revisiting the Perspectives of Bispecific Antibodies under the COVID-19 Pandemic
November 16th, 2020 | 3:00 am EST
Bio Integrates 2020
December 2nd, 2020 | 1:30 pm EST
Webinar | How To Prevent a Terrible, Horrible, No Good, Very Bad Day for Your Life Sciences Start-up: Lessons Learned From Company Formation, Drug Development, Partnering, and Due Diligence Nightmares
October 21st, 2020 | 2:00 pm EDT
NJIPLA - 34th Annual Pharmaceutical/Chemical Patent Practice Update Webinar Series
September 29, 2020
Fish & Richardson Receives Top Firm Rankings and 14 Principals Named 2020 “Life Sciences Stars” by LMG Life Sciences
August 12, 2020
Fish & Richardson Receives Top “Gold” Ranking from IAM Patent 1000 for National Litigation Practice; National Rankings in the Plaintiff Firm and Prosecution Firm Categories
August 11, 2020
Fish & Richardson Featured in Nine Categories of the LMG Life Sciences Awards 2020 Shortlists